Program
lonoctocog alfa
Also written as “rVIII-SingleChain” and “Recombinant single-chain factor VIII (rVIII-SingleChain)”.
Its studies are mostly in Hemophilia A, led by CSL.
Furthest: phase 3, since Nov 19, 20114 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSL | 40 open or running | phase 3since Nov 19, 2011 | Nov 19, 2011 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 19, 2011First study: phase 3 study in Hemophilia AFirst studyNCT01486927 · 175 enrolled · United States, Australia, Austria and more
- Mar 19, 2014Phase 3 study in Hemophilia ANCT02093897 · 84 enrolled · United States, Australia, Austria and more
- Jun 23, 2014Phase 3 study in Hemophilia ANCT02172950 · 246 enrolled · United States, Australia, Austria and more
- Dec 12, 2024Phase 3 study in Hemophilia ANCT06738485 · 62 enrolled · China
TargetBeta
F8 →read by rule
“Coagulation factor VIII exogenous protein”ChEMBL 37, by rule
Other programs on F8
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| antihemophilic factor, human recombinantrule | Takeda | phase 4 | 16 |
| efanesoctocog alfarule | Sanofi | phase 4 | 12 |
| omfiloctocog alfarule | Sinocelltech Group | phase 4 | 6 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06738485Hemophilia A · China | 3 | Completed | Sep 23, 2026 | 62 |
| NCT02172950Hemophilia A · United States, Australia, Austria and more | 3 | Completed | Jan 19, 2021 | 246 |
| NCT02093897Hemophilia A · United States, Australia, Austria and more | 3 | Completed | Aug 2015 | 84 |
| NCT01486927Hemophilia A · United States, Australia, Austria and more | 3 | Completed | Dec 2014 | 175 |
How it is read
Names in the registry
- “rVIII-SingleChain”, 3 entries
- “Recombinant single-chain factor VIII (rVIII-SingleChain)”, 1 entry
Conditions, from the studies’ own filings
- Hemophilia A, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.